keto-bicyclo[3.3.0]octane | 28569-63-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: keto-bicyclo[3.3.0]octane
• 英文别名: cis-Bicyclo<3.3.0>octan-1-on；cis-Bicyclo<3.3.0>octan-2-on；Bicyclo<3.3.0>octan-2-ol；Bicyclo<3.3.0>octan-2-on；2-Bicyclo<3.3.0>octanon；2-Bicyclo[3.3.0]octanon；3,3a,4,5,6,6a-hexahydro-2H-pentalen-1-one
• CAS: 28569-63-3
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: NZTVVUIIJPWANB-UHFFFAOYSA-N

物化性质

• 沸点：
  201.6±8.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-(2-氧代环戊基)丙腈	2-oxocyclopentanepropiononitrile	4594-77-8	C8H11NO	137.181

反应信息

• 作为反应物：
  描述：

  keto-bicyclo[3.3.0]octane 在 正丁基锂 、 四甲基乙二胺 、 甲基锂 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 生成 2-methylbicyclo<3.3.0>oct-2-ene
  参考文献：
  名称：

  Reaction of 1-chloro-2-alkylcycloalkenes with organolithium reagents. A novel cyclopropanation reaction involving the generation of carbenes from vinyl halides

  摘要：

  DOI：

  10.1021/ja00541a022
• 作为产物：
  描述：

  3,4,5,6-tetrahydro-2H-pentalen-1-one 在 氨 、 lithium 作用下， 生成 keto-bicyclo[3.3.0]octane
  参考文献：
  名称：

  (±)-Ingenol的首次全合成

  摘要：

  (+/-)-ingenol的首次全合成已经实现。该合成的主要特点包括使用高度非对映选择性迈克尔反应来固定 C-11 甲基立体化学，以及通过非对映选择性卡宾加成到 Delta13,14 烯烃并入二甲基环丙烷。分子内二恶烯酮光加成-断裂序列导致关键的 C-8/C-10 跨桥头立体化学的建立，这是合成 ingenane 的核心挑战。使用 C-6alpha 羟甲基作为氧化七个连续碳中心的唯一手柄来完成合成。

  DOI：

  10.1021/ja026600a

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• An episulfonium ion mediated ring expansion of 1-alkenylcycloakanols
  作者：Sunggak Kim、Jung Ho Park

  DOI：10.1016/s0040-4039(01)93336-2

  日期：——

  It has been found that TBDMS ethers of 1-alkenylcycloalkanols are readily rearranged to the ring expanded α-(1-phenylthioalkyl)cycloalkanones in high yields via episulfonium ions.

  已经发现1-烯基环烷醇的TBDMS醚易于通过epi磺酸离子以高收率重排至扩环的α-（1-苯硫烷基）环烷酮。
• Iron (III) Perchlorate Adsorbed on Silica Gel: A Reagent for Organic Functional Group Transformations
  作者：Anupama Parmar、Harish Kumar

  DOI：10.1080/00397910701410772

  日期：2007.7

  Fe(ClO4)3(H2O)6 onto chromatographic‐grade silica gel in the presence of organic solvents (S=water, acetonitrile, or lower fatty acids) produces a supported reagent, Fe(ClO4)3(S)6/SiO2. This reagent has been found to be effective for the rapid organic functional group transformations such as dimerization of alkynes, aromatic hydrocarbons, selective oxidation of thiols to disulfides, and transannular reactions in

  摘要 在有机溶剂（S=水、乙腈或低级脂肪酸）存在下，将 Fe(ClO4)3(H2O)6 吸附到色谱级硅胶上会产生一种负载型试剂 Fe(ClO4)3(S)6 /SiO2。已发现该试剂可有效进行快速有机官能团转化，例如炔烃、芳烃的二聚化、硫醇选择性氧化为二硫化物，以及使用杵和研钵在固态研磨时 1,5-环辛二烯中的跨环反应.
• PROCESS FOR PREPARING PURE CYCLODODECANONE
  申请人：Teles Joaquim Henrique

  公开号：US20100191018A1

  公开（公告）日：2010-07-29

  The present invention relates to a process for preparing at least one cyclic compound with Z cycles and 7 to 16 carbon atoms with a keto group, at least comprising the stages: (a1) oxidation of a composition (A), at least comprising one cyclic olefin with Z cycles and 7 to 16 carbon atoms and at least two C—C double bonds, by means of dinitrogen monoxide to give a composition (A1), (a2) separating off the at least one cyclic olefin with Z cycles and 7 to 16 carbon atoms with at least two C—C double bonds from the composition (A1) in order to obtain a composition (A2), and (b) distillative treatment of the composition (A2) from step (a2) in order to obtain a composition (B), comprising the at least one cyclic compound with Z cycles and 7 to 16 carbon atoms with a keto group and less than 1.0% by weight of the at least one compound with Z−1 cycles and 7 to 16 carbon atoms with at least one aldehyde group, where Z can be 1, 2, 3 or 4.

  本发明涉及一种制备至少一种具有Z个环和7到16个碳原子的含酮基的环状化合物的方法，至少包括以下阶段：(a1)将含有至少一种具有Z个环和7到16个碳原子以及至少两个C—C双键的环状烯烃的组合物（A）氧化，通过二氧化二氮，得到组合物（A1）；(a2)从组合物（A1）中分离出至少一种具有Z个环和7到16个碳原子以及至少两个C—C双键的环状烯烃，以获得组合物（A2）；以及(b)对来自步骤（a2）的组合物（A2）进行蒸馏处理，以获得组合物（B），包括具有Z个环和7到16个碳原子的至少一种含酮基的环状化合物，以及少于1.0%的重量的至少一种含有Z−1个环和7到16个碳原子且至少一个醛基的化合物，其中Z可以为1、2、3或4。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。